Sysco Corp.’s biggest intraday stock jump since at least 1980 was just the latest blow to the conventional wisdom that acquirers should brace for a selloff.
As Teva Pharmaceutical Industries Ltd. attempts to revitalize one of this year’s worst-performing drug stocks, a remedy may come in the form of a deal.
Endo Health Solutions Inc.’s recent acquisition designed to lower its tax rate may be following Valeant Pharmaceuticals International Inc.’s blueprint for a lucrative takeover spree.
Actavis Inc., the largest U.S. maker of generic drugs by market value, said it’s in “early stage discussions” to buy Warner Chilcott Plc, the drugmaker that unsuccessfully pursued a sale last year.
Actavis Inc. agreed to sell assets covering four generic drugs in a settlement with U.S. regulators that clears the way for its $8.5 billion acquisition of Warner Chilcott Plc.
After two drug industry suitors already won lower tax rates through Irish acquisitions, investors are speculating Jazz Pharmaceuticals Plc and Alkermes Plc may draw the next bids.
Actavis Inc.’s $5 billion deal to buy Warner Chilcott Plc brings in a new stable of brand-name women’s health drugs. It also comes with headquarters relocated to Ireland and lower taxes for the combined company.
U.S. stocks declined, after the Standard & Poor’s 500 Index climbed four straight weeks, as investors weighed the pace of central bank stimulus efforts amid corporate dealmaking.
Kasowitz, Benson, Torres & Friedman LLP hired insurance recovery litigators Jerold Oshinsky and Linda Kornfeld from Jenner & Block LLP as partners to open the firm’s Los Angeles office.
Actavis Inc., the largest U.S. maker of generic drugs by market value, agreed to acquire Warner Chilcott Plc for about $5 billion excluding net debt in a deal to expand in women’s health and urology.